Nocdurna (Desmopressin Acetate) Patent Expiration, LOE Window & CMS Spending
Nocdurna (Desmopressin Acetate) by Antares: FDA Orange Book LOE 2030-04-13, 7 AB generics, $235K 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Antares |
| FDA Application & Pathway | N022517 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2030-04-13 |
| Orange Book Patents (*PED Extensions) | 4 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 7 |
| 2024 CMS Total Public Spend | $235K |
| 2024 Medicare Part D Spend | $219K |
| 2024 Medicaid Spend | $16K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |